OssDsign announced that 500 patients have now been treated in the U.S. with OssDsign Catalyst nanosynthetic bone graft.
Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue.
The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry and TOP FUSION, the premarket clinical trial, in which patient enrolment was completed in April 2022.
“Since June 2022, when we reached the first 100 patients, momentum has significantly accelerated. The rapid growth in the number of patients treated emphasizes the traction of OssDsign Catalyst and the increasing interest from surgeons in using the product for spinal fusion surgeries. Together with the postmarket safety report and recent clinical data published on OssDsign Catalyst, reaching the 500-patient milestone is creating a stronger basis for the continued commercialization,” said Morten Henneveld, CEO of OssDsign.
OssDsign announced that 500 patients have now been treated in the U.S. with OssDsign Catalyst nanosynthetic bone graft.
Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and...
OssDsign announced that 500 patients have now been treated in the U.S. with OssDsign Catalyst nanosynthetic bone graft.
Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue.
The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry and TOP FUSION, the premarket clinical trial, in which patient enrolment was completed in April 2022.
“Since June 2022, when we reached the first 100 patients, momentum has significantly accelerated. The rapid growth in the number of patients treated emphasizes the traction of OssDsign Catalyst and the increasing interest from surgeons in using the product for spinal fusion surgeries. Together with the postmarket safety report and recent clinical data published on OssDsign Catalyst, reaching the 500-patient milestone is creating a stronger basis for the continued commercialization,” said Morten Henneveld, CEO of OssDsign.
Copy to clipboard 
